VIGL News

Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. Seven biotechs have gone public so far in 2022. While the group performed relatively well in the first quarter, returns...read more

In the first month of 2022, eight IPOs raised $1.7 billion, mostly tech and healthcare. Private equity giant TPG headlined the month, followed by semiconductor play Credo Technology; the other six were either biotechs or micro-caps. Market conditions weighed on activity, and a number of companies pulled their deals, with four postponements and six withdrawals during the month....read more

The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Nine IPOs and three SPACs submitted initial filings. CinCor Pharma (CINC) upsized and priced at the midpoint to raise $194 million at a $612 million market cap. CinCor's lead candidate has been designed to use a differentiated mechanism of action...read more

Vigil Neuroscience, a Phase 1 biotech developing antibody therapies for neurodegenerative diseases, raised $98 million by offering 7 million shares at $14, below the range of $15 to $17. The company is addressing microglial dysfunction, which has been implicated in neurodegenerative diseases. Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially...read more